"LIVALO has been the leading product in our cardiovascular portfolio in Asia since 2003," said Ben Stakely, president and CEO of Kowa Pharmaceuticals. "We are excited to bring our flagship product to the U.S. to help patients reach their LDL-C goals."

"Lilly is committed to providing innovative solutions to patients in need and is excited to collaborate with Kowa Pharmaceuticals America, Inc. to bring this new statin to the market," said Javan Collins, vice president of Cardiovascular Business Unit, Lilly.  "LIVALO offers physicians another option for patients trying to lower their LDL-C."

Kowa Pharmaceuticals and Lilly last year announced a co-promotion agreement to commercialize LIVALO in the U.S. in which both companies will provide sales force resources and share development and commercialization costs.

SOURCE Kowa Pharmaceuticals America, Inc.; Eli Lilly and Company